Tiragolumab

Tiragolumab 是一种与 T 细胞免疫球蛋白和 ITIM 结构域 (TIGIT) 结合的免疫检查点抑制剂。Tiragolumab 单独或与 PD-L1 抑制剂 Atezolizumab 联合使用，可能对多种实体恶性肿瘤有效，尤其是非小细胞肺癌。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥5825.00

4660.00

- +
10mg

￥9387.00

7510.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab, may be effective against multiple solid malignancies-most notably non-small cell lung cancer^[1]^[2].

[1]. Mohammed Sqalli Houssaini, et al. Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting. Cancer Treat Res Commun. 2020;25:100239.
[2]. Tiragolumab Impresses in Multiple Trials. Cancer Discov. 2020 Aug;10(8):1086-1087.